Healthcare organizations are moving slow with genAI tools: They’re concerned with the tech’s risks and unclear industry regulations. Here’s what it means for AI developers.
Walmart is expanding its specialty pharmacy presence: With a multi-billion dollar market opportunity in-play, its decision to open 25 new autoimmune-focused specialty pharmacies across the US is smart business.
CVS Caremark to pay $45M to Illinois in PBM settlement: While it may seem like the walls are finally closing in on PBMs, paying multi-million dollar settlements is just part of doing business for pharma’s middlemen.
New GLP-1 users are more likely to have obesity than diabetes: The trend is concerning for some patients, but not for Big Pharma.
Headway’s valuation hits $2.3B after closing its Series D: The startup tackles two big problems in the mental health space. Investors are paying close attention.
Humana’s CenterWell to open senior primary care clinics at Walmart stores: Despite recent headwinds in the retail primary care space, we think CenterWell’s deal with Walmart will prove to be symbiotic.
Mayo Clinic, Epic, Abridge develop genAI tool for nurses: The platform will help relieve nurses’ administrative burden, but they still have concerns about AI in healthcare.
40% of drugs approved in the past decade will be blockbusters: We unpack a new forecast of projected drug sales and explore if forthcoming industry headwinds will be enough to curb revenue growth.
Hims & Hers adds longtime Novo exec to its board: Here’s what the appointment tells us about Hims & Hers’ ambitions in the GLP-1 space.
PwC expects healthcare costs to grow 8% in 2025: Below, we detail the primary drivers and how we expect health insurers to combat them.
Physician burnout is declining: While there’s modest improvement in burnout rates, employers who staff doctors need to make them feel more valued at work.
GCI Group rolls out health influencer marketing service: We unpack the details of the new offering from the healthcare communications agency and explore why it could be positioned to succeed in this increasingly crowded space.
Big Pharma’s missed opportunity to connect with consumers in local markets: Most drugmakers don’t have country-specific mobile apps or social media accounts.
Teladoc partners with Brightline for pediatric mental healthcare: Here’s why Teladoc’s tie-up with the virtual behavioral health startup makes perfect sense from both a patient acquisition and financial standpoint.
Boehringer Ingelheim, GoodRx offer cheaper version of Humira biosimilar: Increased competition in the space should help reduce prices for cash-strapped Americans, but not fast enough.
A lifeline for digital therapeutics? A proposal to reimburse doctors for treating patients through digital therapies could help a small group of DTx players, but it might be too late for struggling companies.
Where patients get GLP-1 prescriptions: In-person clinics with familiar doctors are the current preference. However, we still see a huge market opportunity for online providers.
UnitedHealth Group records $4.2B in Q2 profit: We unpack the financials behind UnitedHealth Group’s big Q2 and explore why reining in the influence of massive healthcare companies is so difficult.
Caregivers in the US are burned out: We explore the opportunity healthcare and pharma brands have to create marketing strategies specifically tailored to caregivers.
Docs use genAI to appeal denied prior authorizations: Here’s why physicians are turning to the tech for appeals and where we think the prior authorization standoff between insurers and providers is headed.